Several caged Garcinia xanthone natural products have potent bioactivity and a documented value in traditional eastern medicine. Previous synthesis and SAR studies of these natural products resulted in the identification of the pharmacophore represented by the structure of cluvenone. In the current study, we examined the anti-cancer activity of cluvenone and conducted gene expression profiling and pathway analyses. Cluvenone was found to induce apoptosis in T-cell acute lymphoblastic leukemia cells (EC 50 = 0.25 μM) and had potent growth inhibitory activity against the NCI60 cell panel, including those that are multi-drug resistant, with a GI 50 range of 0.1 μM -2.7 μM. Importantly, cluvenone was about 5-fold more potent against a primary B-cell acute lymphoblastic leukemia compared to peripheral blood mononuclear cells (PBMC) from normal donors suggesting that it has significant tumor selectivity. Comparison of cluvenone's growth inhibitory profile to those in the NCI database revealed that compounds with similar profile to cluvenone were mechanistically unlike known agents, but were associated with cell stress and survival signaling. Gene expression profiling studies determined that cluvenone induced activation of the MAPK and NrF2 stress response pathways. Furthermore, cluvenone was found to induce intracellular ROS formation. Lastly, the modulation in expression of several genes associated with T-cell and NK cell activation and function by cluvenone suggests a role as an immune-modulator. The current work highlights the potential of cluvenone as a chemotherapeutic agent and provides support for further investigation of these intriguing molecules with regard to mechanism and targets. 
Introduction
According to the American Cancer Society, there were nearly 1.5 million men and women diagnosed with cancer in the US in 2009. It is projected that about 40 % of these individuals will die of their disease. The current annual cancer incidence rate corresponds to one out of every two men, and one out of every three women being diagnosed with cancer within their lifetime.
The main obstacle for successful treatment is resistance to current therapies. Not only are the current chemotherapeutic agents ineffective against many cancers, especially relapsed cancers, but there is significant toxicity associated with these therapies. Therefore, it is essential to intensively investigate novel agents that are not only effective against refractory cancers, but are also tumor selective and thus less toxic.
The tropical trees of the genus Garcinia, found in lowland rainforests of Southeast Asia, are widely known for their use in folk medicine (1, 2) . Phytochemically, these trees are recognized as a rich source of xanthone and xanthonoid natural products that hold high pharmaceutical potential. Gambogic acid (GA) is the main active component of gamboge, a dry resin secreted from Garcinia hanburyi. It has been well established that GA induces apoptosis in multiple tumor cell lines including T47D breast cancer cells and MGC-803 human gastric carcinoma cells at sub-micromolar to low micromolar concentrations (3) (4) (5) . Furthermore, GA has demonstrated efficacy in several human tumor xenograft models and has entered clinical trials in China for the treatment of cancer (6) (7) (8) (9) .
Previously, we have reported a new strategy for the chemical synthesis of the Garcinia natural products (10, 11) . The synthesis is short, efficient, and stereo-selective, and allows access to a variety of these compounds and related analogs. This technology not only Pharmacia, Piscataway, NJ) at 400g for 30 min followed by two washes with RPMI 1640. The content of lymphoblasts in these patient samples, as determined by Wright stain, was ≥ 80%.
Primary B-cell ALL and peripheral blood mononuclear cells (PBMC) obtained from normal donors were treated with increasing concentrations of cluvenone for 48 h and then viable cell numbers were determined by counting in a hemocytometer.
Agilent Whole Human Genome 4 X 44K arrays

Treatment of Cells with cluvenone and isolation of total RNA.
CEM cells were treated in quadruplicate with 0.3 μM cluvenone, or with 0.1% DMSO (control) for 2 and 4.5 h. Total RNA was isolated from 5-10 x 10 6 cells using the ArrayGrade™
Total RNA Isolation Kit (SuperArray Bioscience Corp., Frederick, MD) according to the manufacturer's recommendations. The integrity and concentration of the total RNA was assessed on a 2100 Bioanalyzer (Agilent Technologies), using the RNA 6000 Nano LabChip.
The RNA integrity (RIN number) ranged from 9.5 to 10.0.
Microarray Analysis
RNA (500 ng/reaction) was amplified (1-round) and labeled with Cyanine 3 (Cy3, control) and their interconnectedness, thus representing a systems biology approach (14) . The Impact
Factor is equivalent to the negative log of the global probability of having both a statistically significant number of differentially expressed genes, and a large perturbation in the given pathway. Thus, Impact Factor values indicate the likelihood that the listed pathway is truly affected in the treated case, and is not a spurious result.
Real-Time RT/PCR
cDNA was transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). by an extension at 60°C for 1 min. The final step of the protocol included a melt curve from 60°C to 100°C in 0.5°C interval at 10 sec per interval. 
Measurement of intracellular ROS
Results
In a previous report (12) Although cluvenone is cytotoxic to a broad range of tumor cells including multidrugresistant cancer cells, it must demonstrate tumor selectivity in order to be an effective chemotherapeutic agent. To determine whether cluvenone has any selectivity for cancer cells over normal cells, we examined the effect of cluvenone in a primary human leukemia and PBMC obtained from a normal donor. Previously, we have found that cytotoxicity results from viability assays using primary cells from normal donors and patients correlates well with in vivo data, as opposed to data from similar assays using cell lines (15) . For these experiments, primary cells were exposed to increasing concentrations of cluvenone for 48 h and then viable cell numbers were determined. The results shown in Figure 3 indicate that cluvenone is 4.7-fold more toxic to leukemia cells (IC 50 =1.1 μM) than PBMC from normal donors (IC 50 =5.2 μM).
Interestingly, in the same experiment, GA was 3.9-fold more toxic to B-ALL cells than PBMC suggesting that it may have greater toxicity to normal cells compared to cluvenone (not shown). anticipated that cluvenone will be well tolerated at the low doses which are therapeutically effective.
In order to gain insight into the mechanism of action of cluvenone, a COMPARE analysis was conducted using the results of the NCI60 cell panel screen. The results of this analysis determined that molecules with a similar cytotoxicity profile to cluvenone were of completely different chemical structures ( Figure 4A ), and were not similar to standard agents.
Furthermore, using 3D Mind tools, the top 6 ranked molecules and GA were mapped to the Q region of a self organizing map (SOM), distal to agents with known mechanism of action ( Figure   4B ). The Q region of the SOM includes bioactive molecules with yet unknown mechanisms of action but which have recently been implicated to activate signaling pathways involved in cell stress and survival (16, 17) . These findings highlight the structural uniqueness of cluvenone and members of the caged Garcinia xanthones as well as demonstrate the potential of the current research for therapeutic application to cancers refractory to standard chemotherapy.
Intrigued by the results of the SOM suggesting a novel mechanism of action and to further investigate the mode of action of cluvenone, gene expression profiling experiments were conducted using Agilent Whole Genome 4 X 44K arrays (accession number GSE23536 in GEO database). In these experiments, CEM cells were treated in quadruplicate with vehicle (DMSO) or with 0.3 μM cluvenone for 2 and 4.5 h. Analysis of the microarray data using GeneSifter software revealed that 191 or 250 genes were altered in expression at least 1.7-fold (adjusted p value <0.005) by cluvenone treatment for 2 or 4.5 h, respectively. The fold change cutoff was selected based on a report of an independent laboratory demonstrating decreased expression of telomerase reverse transcriptase (TERT) in response to treatment with GA (18, 19) . In agreement with this report, our data indicated that TERT expression was decreased 1.7-fold by cluvenone indicating that a 1.7-fold change in expression was a valid cutoff. Treatment of CEM cells with cluvenone appears to significantly affect adherens junction signaling (Table 1A) . Though this result is based on a small change (-1.7-fold) in the T-cell specific transcription factor (TCF7), this gene is central in adherens junction signaling involving the Wnt pathway. Furthermore, deregulated transcription of the full length TCF7 isoform appears to be involved in prostate and colon cancers (25) (26) (27) . This may be due, in part, to the transcriptional activation of c-myc by complexes of Β−catenin and members of the TCF family ultimately resulting in enhanced cell proliferation (28) . Interestingly, cluvenone decreased the expression of both TCF7 and c-myc (greater than 2-fold) suggesting that it may have a role in suppressing signaling through the Wnt pathway associated with prostate and colon cancer (29) .
Genes that are central to the regulation of the actin cytoskeleton, ITGAV and ITGB2, are significantly up-regulated by cluvenone at both time points (Table 1A and B) suggesting that cluvenone can affect activities associated with the actin cytoskeleton such as cell motility and adhesion. These activities are particularly important for T-cell function as is protein export (Table 1B) The simple synthetic GA analog, cluvenone, has significant cytotoxicity at nanomolar concentrations against a broad range of tumor types including multi-drug resistant tumors with leukemia being the most sensitive tumor type, followed by colon, breast, prostate, and renal cancers. Since breast, prostate, and colon cancers are among the most common cancers in the U.S., cluvenone may have significant value as a chemotherapeutic agent. Our results indicate that cluvenone is an effective inducer of apoptosis, a required attribute for an effective chemotherapeutic agent. Furthermore, the observed differential cytotoxicity between leukemia cells and PBMC from normal donors, suggesting that cluvenone has tumor selectivity, further adds to the potential value of cluvenone in the treatment of cancer.
ROS was not detectable at times tested earlier than 5.5 h (data not shown). To determine whether induction of ROS accounted for the cytotoxicity of cluvenone, PC3 cells were treated with cluvenone in the presence and absence of the antioxidant, N-acetylcysteine. Cell proliferation was then measured after 48 h in a
The unique structure and activity profile of cluvenone is consistent with the results of the COMPARE analysis indicating that compounds most similar to cluvenone map to the Q region of a SOM, a region including molecules with unknown mechanisms of action, but associated with signaling involved in cell stress and survival. Cellular stress generated by cluvenone appears to be due to the generation of ROS as determined for GA (31) . In a recent study, GA induced the formation of ROS in hepatoma cells resulting in loss of mitochondrial membrane potential, release of cytochrome c, and apoptosis. Furthermore, these activities were associated with phosphorylation of JNK and p38, key members of the MAPK stress signaling pathway.
Interestingly, the anti-oxidant, N-acetylcysteine, only partly reversed the activation of JNK and p38, and the induction of apoptosis in GA-treated cells, suggesting that additional mechanisms account for the cytotoxicity of GA. Like many natural products, both GA and cluvenone likely have multiple targets and mechanisms of action. For instance, in addition to inducing ROS, GA has been shown to bind to and inhibit the anti-apoptotic activities of the Bcl-2 family of proteins (32) . These activities would result in a two-pronged attack on tumor cells with the induction of cell stress and the release of an apoptotic block, not uncommon in tumor cells. 
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Most recently, it has been reported that the oxidative stress induced by GA results in DNA damage as detected by a comet assay and evidenced by the activation of p53/p21 through the ATR-Chk1 pathway (33) . It is important to note, however, that activation of DNA damage response pathways can occur in the absence of DNA strand breaks and can occur in response to alteration in chromatin structure or, to depletion of nucleotide pools (34) . Furthermore, it is important to appreciate that DNA damage measured in the comet assay is not necessarily a result of direct genotoxicity as mitochondrial or membrane damage can cause extensive DNA fragmentation via apoptosis or necrosis (35) . Whether cluvenone induces DNA damage is yet to be determined. However, the results of the Agilent Whole Genome array analysis did not indicate increased expression, at either time point, of genes encoding DNA repair enzymes including but not limited to RAD17, RAD51, PARP1,2, POL B, POLG typically induced upon DNA damage (36) . Furthermore, neither cluvenone nor GA map to a region to which known DNA damage inducing agents map on a SOM.
The mitochondria have recently emerged as an important target for cancer therapy due to the bio-energetic differences between normal and cancer cell mitochondria (37) . In addition, the mitochondria are an invariant target common to all cells and in which mutations are very rare (37) . The rare mutation event in mitochondria suggests a low probability for the development of resistance to agents targeting mitochondria. It is well established that many mitocans target components of the electron redox chain, leading to ROS production and activation of the intrinsic pathway of apoptosis in cancer cells. Examples of such drugs include the vitamin E analog, α-TOS, and N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide). The pro-oxidant mechanism of 4-HPR activity has not been clearly identified, although it is likely to act as an inhibitor of at least one of the complexes along the electron transport chain (38) . We 
